Trial Profile
A Phase III Randomized, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms SHARP
- Sponsors Bayer
- 08 Jun 2021 Results of meta analysis of Four eligible phase III studies (REFLECT, SHARP, Asia-Pac and IMbrave150) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 12 Sep 2017 Results of exploratory analysis assessing overall survival by using baseline platelet count from three studies (SHARP, AP, and RESORCE) presented at the 42nd European Society for Medical Oncology Congress
- 01 Sep 2017 According to a Bayer media release, data for overall survival by platelet count at baseline will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.